Crossmark

A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial

Crossref DOI link: https://doi.org/10.1186/s12962-024-00516-5

Published Online: 2024-01-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Jiahui

Xu, Chaoqun

Yuan, Suyun
License Information

Text and Data Mining valid from 2024-01-27

Version of Record valid from 2024-01-27
More Information

Article History

Received: 22 November 2023

Accepted: 17 January 2024

First Online: 27 January 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below